IQVIA Holdings Inc. (NYSE:IQV ) Q3 2024 Results Conference Call October 31, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations & Treasury Ari Bousbib - Ch...

Contract research firm IQVIA lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges.

IQV's TAS and RD&S revenues are anticipated to have increased, while CSMS revenues are likely to have dipped in the third quarter of 2024.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024....

While IQV benefits from its market leadership, data-driven innovation and global expansion, it must navigate pricing pressure.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IQVIA (IQV) rides high on robust segmental performance, boosting the company's top line. However, elevated operating expenses and weak liquidity are a major concern.

Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Investors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Waters (WAT). But which of these two companies is the best option for those looking for underv...

Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street e...

IQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.

IQVIA Holdings (IQV) came out with quarterly earnings of $2.64 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to earnings of $2.43 per share a year ago.

Contract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.

IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.